'Lack of clarity' over new hospital plans
A review group set up to look at the plans, which the government approved last week, has highlighted "a lack of clarity and transparency about the decision-making" and "an absence of strategic healthcare, workforce and procurement planning".
The panel has made 34 key findings and 20 recommendations to tackle the issues raised as the business case for the project is developed.
Health Minister Tom Binet said he was confident they would "be able to address all the key findings and recommendations and assuage any public misgivings".
The review group said while the need for new healthcare facilities was urgent, more detail about decision making and costs would make the future phases of the project easier.
Talking about the business case for the new hospital, Deputy Jonathan Renouf said: "It is all very well wanting to 'get things done', but we need to know that what is being done is the right thing."
"This is the largest capital project the island has ever embarked on, and the panel has major concerns that there appears to be an ongoing lack of transparency which means that the Outline Business Case does not meet the expected standard to justify funding decisions of this scale."
Responding to the panel's concerns, the Health Minister, Deputy Tom Binet said: "The report is likely to cause a good deal of unnecessary concern.
"There is nothing...to suggest that progress towards the delivery of new healthcare facilities should be slowed and I am confident that the team will be able to address all the key findings and recommendations and assuage any public misgivings."
Follow BBC Jersey on X and Facebook. Send your story ideas to channel.islands@bbc.co.uk.
Major shake-up proposed for Jersey health services
Government of Jersey
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Sea swim in office wear raising money for charity
Workers in Guernsey have entered the sea in office clothing in a bid to raise money for a heart charity. Keen sea swimmer Tristan Boscher, 47, said the 'Port Soiffice' annual charity swim at Port Soif had been running for 11 years. "I had my own heart attack and went to Southampton and had triple bypass surgery so since then we've been doing it for heart charities," he said. Mr Boscher said proceeds would go to Guernsey's Chest and Heart, a charity which offers screening to people between the ages of 25 and 75. Mr Boscher, who swims all year round, said five years had passed since he had the heart attack. He added that the heart attack happened the day after he had taken part in the Port Soiffice. "It just came out of the blue," he said. "I was very active." He said the chosen charity was a good one to support to try to "prevent people from going through heart conditions and identifying any issues early on". 'Bobbing and gobbing' Mr Boscher said the idea to wear suits during the swim originated due to the "play on words". "Port Soif leant itself to Port Soiffice," he added. "When we first did it we were in these suits and we had a desk and a computer in the water... that was the start of it really." Mr Boscher's friend Sue Duport, committee member for Guernsey's Swim All Seasons, has been taking part in the fundraiser for three years. Ms Duport said the charitable event was "really good" for mental health. "It has taken away a lot of isolation for a lot of people," she said. "It's always laughter, bobbing and gobbing and it's just a really good experience." More news stories for Guernsey Listen to the latest news for Guernsey Follow BBC Guernsey on X and Facebook and Instagram. Send your story ideas to Related internet links Guernsey Chest and Heart
Yahoo
2 days ago
- Yahoo
AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases. Sign in to access your portfolio
Yahoo
4 days ago
- Yahoo
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
Investment will support AstraZeneca's ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company's largest single investment in a facility to date WILMINGTON, Del., July 21, 2025--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California Continuous manufacturing expansion in Mount Vernon, Indiana Specialty manufacturing expansion in Coppell, Texas New sites to supply clinical trials Our growing research and development investment in novel medicines Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US. Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here." Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth." Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines." Notes AstraZeneca in the US The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. We employ more than 18,000 people and support 92,000 jobs overall across the United States. In 2024 we contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy. Today the US represents 42% of our Total Revenue with an ambition to reach 50% by 2030. This underscores the critical role the US plays in our ability to deliver on our ambition to launch 20 new medicines by the end of the decade. AstraZeneca AstraZeneca (Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca. View source version on Contacts Media Inquiries Fiona Cookson +1 212 814 3923Rachel Ross +1 202 427 1621 US Media Mailbox: usmediateam@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
